PAGE 228 - ENZYME KINETICS

Michaelis-Menten kinetics

• "Km is the substrate concentration needed for an enzyme to reach a rate of 1/2 Vmax, and is inversely related to the affinity of the enzyme for its substrate."
  • Every enzyme reaction has a maximum possible speed, called Vmax (maximum velocity - the fastest the enzyme can convert substrate to product, when it's completely saturated with substrate, like a factory running at full capacity).
  • Km ("Michaelis constant") is a number that tells you how much substrate is needed to get the enzyme working at half of that maximum speed.
  • "Inversely related to affinity" means: a low Km = high affinity (the enzyme grabs its substrate easily, doesn't need much of it around to work fast) and a high Km = low affinity (the enzyme needs a lot of substrate floating around before it works efficiently, i.e., it doesn't "stick" to the substrate well).
  • Think of it like a person's attraction to coffee: someone with "high affinity" for caffeine gets alert after one sip (low Km). Someone with "low affinity" needs three cups before feeling anything (high Km).
• "Vmax is directly proportional to the enzyme concentration."
  • If you have more enzyme molecules in the system, the top speed you can reach goes up proportionally. More workers on a factory floor = higher maximum output.
• "Most enzymatic reactions follow a hyperbolic curve (ie, Michaelis-Menten kinetics); however, enzymatic reactions that exhibit a sigmoidal curve usually indicate positive cooperativity in substrate binding (eg, aspartate transcarbamoylase)."
  • If you plot Velocity (V, y-axis) against Substrate concentration [S] (x-axis), most enzymes produce a curve that rises quickly then flattens out (like a hyperbola) - this flat part is Vmax, where the enzyme is saturated and adding more substrate doesn't speed things up further.
  • Some special enzymes instead give an S-shaped (sigmoidal) curve. This happens with enzymes that have several binding sites that talk to each other - once the first substrate molecule binds, it makes it easier for the next one to bind (like a lock that gets looser once you turn the first key). This is called positive cooperativity - the classic textbook example is hemoglobin (oxygen binding) or the enzyme aspartate transcarbamoylase (used in making DNA/RNA building blocks).

Effects of enzyme inhibition (graph)

• Competitive inhibitor: the curve needs more substrate to reach the same Vmax (shifts the curve right, Km increases) but Vmax is unchanged if you add enough substrate.
• Noncompetitive inhibitor: Vmax drops (curve doesn't reach as high) but Km stays the same.

Lineweaver-Burk plot

• "The closer to 0 on the Y-axis, the higher the Vmax."
  • The Y-intercept (where the line crosses the vertical axis) = 1/Vmax. Since it's an inverse, a point closer to zero on the Y-axis means 1/Vmax is a small number, which means Vmax itself is a large number.
• "The closer to 0 on the X-axis, the lower the Km."
  • The X-intercept = -1/Km. A point closer to zero means Km is large... wait, actually in this context it's saying if the intercept is close to zero (small magnitude), then 1/Km is small, so Km is large. But the actual line in the text states "closer to 0 on X axis, the lower the Km" - meaning the further left (more negative, further from zero) the intercept, the higher the Km. Either way, the key takeaway: X-intercept tells you about Km, Y-intercept tells you about Vmax.
• "Reversible competitive inhibitors cross each other, whereas noncompetitive inhibitors do not."
  • On a Lineweaver-Burk plot, if you draw the line for the drug-free enzyme and then the line when a competitive inhibitor is present, the two lines will cross at the same Y-intercept (same Vmax, since Vmax is unchanged by competitive inhibition) but different X-intercepts (different Km).
  • For a noncompetitive inhibitor, the lines are parallel-ish but shift so Vmax changes (different Y-intercept) while Km stays the same (same X-intercept) - so they don't cross at the Y axis in the same way.
• "Competitive inhibitors increase Km." Because you need more substrate to overcome the competition and reach half-maximal speed - affinity looks reduced.

The Competitive vs Noncompetitive Inhibitor Table

• Resemble substrate: Competitive inhibitors (both reversible and irreversible) = Yes, they look like the substrate so they can fit in the same slot. Noncompetitive = No, they don't need to resemble the substrate since they bind elsewhere.
• Overcome by ↑[S]: Can you beat the inhibitor by flooding the system with more substrate? For reversible competitive inhibitors = Yes (substrate can out-compete the inhibitor by sheer numbers, like more people rushing a single door). For irreversible competitive inhibitors = No (once bound, it's bound permanently/covalently - like the door being welded shut). For noncompetitive = No (adding more substrate doesn't help because the enzyme is broken regardless).
• Bind active site: Reversible competitive = Yes; Irreversible competitive = Yes; Noncompetitive = No (binds elsewhere, called an "allosteric site").
• Effect on Vmax: Reversible competitive = Unchanged (you can still reach full speed if you add enough substrate); Irreversible competitive = ↓ (decreased, because some enzyme is permanently disabled, reducing effective enzyme amount); Noncompetitive = ↓ (decreased, because even at high substrate the broken enzymes can't work).
• Effect on Km: Reversible competitive = ↑ (increased, looks like lower affinity); Irreversible competitive = Unchanged; Noncompetitive = Unchanged.
• Pharmacodynamics (drug behavior term): Reversible competitive = ↓ potency (potency = how much drug dose is needed for an effect; here it's describing the substrate's apparent potency being reduced); Irreversible competitive = ↓ efficacy (efficacy = maximum effect achievable); Noncompetitive = ↓ efficacy.

PAGE 229 - PHARMACOKINETICS

Bioavailability (F)

• "Fraction of administered drug reaching systemic circulation." In simple words: if you swallow a pill, not all of the drug makes it into your bloodstream - some is lost. F is the percentage that actually makes it in.
• "For an IV dose, F = 100%." IV = intravenous, injected straight into a vein, so it goes 100% directly into the blood - none is lost, so F=1 (100%) by definition. This is the reference standard.
• "Orally, F typically <100% due to incomplete absorption and first-pass metabolism."
  • Incomplete absorption: some of the swallowed drug simply doesn't get absorbed through the gut wall.
  • First-pass metabolism: after absorption from the intestine, blood carrying the drug goes straight to the liver before reaching the rest of the body (via the portal vein). The liver is the body's chemical processing plant and may break down/inactivate a chunk of the drug before it ever reaches general circulation. So oral drugs often "lose" potency before they even get a chance to act.
• "Can be calculated from the area under the curve of a plot of plasma drug concentration over time." If you plot drug level in the blood (Y-axis) vs time (X-axis) after giving a dose, the total area under that curve (AUC) reflects total drug exposure. Comparing the AUC of an oral dose to the AUC of an IV dose (same amount of drug) tells you what fraction actually got into the bloodstream.
• Formula: F = (AUCoral × Dose_IV) / (Dose_oral × AUC_IV)
• The graph: Shows plasma concentration rising and falling over time after a dose; the shaded blue area (AUC-IV) is larger/complete, while the pink area (AUC after oral) is smaller, showing loss of drug.

Volume of distribution (Vd)

• "Theoretical value that relates drug amount to plasma concentration." This is NOT a real physical volume in the body - it's a calculated number representing how "spread out" a drug is.
• Formula: Vd = amount of drug in the body / plasma drug concentration.
• "Drugs may be distributed in more than one compartment... increase Vd (↓ protein binding, ↑ Vd)."
  • If a drug sticks to plasma proteins (like albumin) it stays trapped in the blood, giving a LOW Vd. If it's less protein-bound, it escapes into tissues, spreading throughout the body, making the calculated Vd look artificially HIGH (higher than actual body volume, sometimes even higher than total body water!).
• "Hemodialysis is most effective for drugs with low Vd."
  • Hemodialysis is the machine-based blood-filtering process used in kidney failure or drug overdose. It can only clean out drug that is actually present in the blood. If a drug has a low Vd (mostly stays in blood/ECF, not hidden in fat/tissues), dialysis can pull it out effectively. If Vd is high (drug is hiding in fat and tissues all over the body), dialysis can't reach it.

• Low Vd → stays in the blood vessels (Intravascular compartment) → typical of large or charged molecules (they can't cross vessel walls easily; charge makes them water-soluble and unable to slip through fatty cell membranes) e.g. large proteins like heparin.
• Medium Vd → spreads into ECF (Extracellular Fluid - the fluid outside cells, i.e., blood plasma + fluid between cells) → typical of small hydrophilic (water-loving) molecules that can leave blood vessels but can't enter cells.
• High Vd → spreads into "All tissues including fat" → typical of small lipophilic (fat-loving) molecules that easily cross cell membranes (which are made of fat/lipid) and molecules that bind heavily to tissue proteins rather than blood proteins.

Clearance (CL)

• "The volume of plasma cleared of drug per unit time." Imagine your kidneys/liver as filters continuously "cleaning" a certain volume of blood every minute, removing the drug from it. Clearance tells you how many mL (or L) of plasma get completely cleaned of the drug per minute/hour.
• "Clearance may be impaired with defects in cardiac, hepatic, or renal function." Because the organs responsible for removing/breaking down drugs are the heart (delivers blood to organs), liver (metabolizes drugs), and kidneys (excrete drugs). If any of these fail, clearance drops and drug accumulates.
• Formula: CL = rate of elimination of drug / plasma drug concentration = Vd × Ke (Ke = elimination rate constant, a number describing how fast first-order elimination happens).

Half-life (t1/2)

• "The time required to eliminate 1/2 of the drug from the body." Simple: how long it takes for the drug level in blood to drop by half.
• "Steady state is a dynamic equilibrium in which drug concentration stays constant (ie, rate of drug elimination = rate of drug administration)." When you take a drug repeatedly (e.g., daily), eventually the amount going in each dose equals the amount being cleared out between doses - the level plateaus. This plateau is "steady state."
• "In first-order kinetics, a drug infused at a constant rate takes 4-5 half-lives to reach steady-state level. It takes 3.3 half-lives to reach 90% of the steady-state level." This is a mathematical fact about exponential accumulation - practically, doctors know that after about 4-5 half-lives of continuous dosing, the drug level in blood has essentially maxed out and stabilized.
• Formula: t1/2 = (0.7 × Vd) / CL (for first-order elimination). This tells you half-life depends on both how "spread out" the drug is (Vd) and how fast it's cleared (CL).
• The table (# of half-lives vs % remaining): after 1 half-life, 50% remains; after 2, 25%; after 3, 12.5%; after 4, 6.25%. This shows exponential decay - each half-life cuts the remaining amount in half again.

Dosage calculations

• Loading dose = (Cp × Vd) / F. A loading dose is a bigger first dose given to rapidly bring blood levels up to the target therapeutic level immediately (instead of waiting several half-lives). Cp = target plasma concentration you want to achieve; you need more drug if Vd is large (drug will "dilute" into a bigger space) and more if bioavailability F is low (since some will be lost).
• Maintenance dose = (Cp × CL × τ) / F. A maintenance dose is the regular repeated dose needed to KEEP the level steady once you've reached it - it just needs to replace whatever amount is cleared out (CL) over the dosing interval (τ = tau, the time between doses).
• "In renal or liver disease, maintenance dose ↓ and loading dose is usually unchanged." Diseased kidneys/liver clear drug slower (↓CL), so you need a smaller regular dose to avoid buildup/toxicity. But the loading dose doesn't depend on clearance - it depends on Vd - so it stays the same.
• "Time to steady state depends primarily on t1/2 and is independent of dose and dosing frequency." No matter how big your dose is or how often you give it, the time it takes to reach steady state is fixed by the drug's inherent half-life (it just always takes ~4-5 half-lives, this is a property of the drug's elimination speed, not the dosing).
• "Does not apply for continuous infusions." because in a continuous IV drip there is no "dosing interval," the drug is going in constantly, so the maintenance dose formula that includes τ (a discrete interval) doesn't apply the same way.

PAGE 230 - DRUG METABOLISM & ELIMINATION

Drug metabolism

• "Drugs can be metabolized by either or both phase I and phase II reactions." The body has a two-step chemical modification system to convert drugs so they can be excreted.
• "These reactions serve to bioactivate or deactivate substances, and do not have to take place sequentially (eg, phase I can follow phase II first)." Sometimes Phase I turns an inactive "prodrug" into its active form, or an active drug into an inactive one. The order isn't fixed - though usually Phase I happens first, some drugs go straight to Phase II.
• "Geriatric patients lose phase I first." As people age, the liver enzymes responsible for Phase I reactions tend to decline earlier/faster than Phase II enzymes - "Geriatrics only get half a chance" is a classic mnemonic (Phase I declines first in the elderly).
• "Patients who are slow acetylators have ↑ adverse effects from certain drugs (eg, isoniazid)." "Acetylation" is a Phase II reaction. Some people genetically have slower acetylation enzymes ("slow acetylators") - they can't clear certain drugs (like isoniazid, a TB drug) as fast, so the drug builds up and causes more side effects (like nerve damage/peripheral neuropathy with isoniazid).

• Takes lipophilic drugs (fat-soluble) and chemically modifies them via Oxidation, Reduction, Hydrolysis - these are basic chemistry reactions that add or remove electrons/water to the drug molecule.
• The enzymes doing this are mostly the Cytochrome P450 (CYP450) family - a huge group of liver enzymes.
• Result: a "Slightly polar metabolite (active or inactive)" plus "Reactive oxygen species" (byproducts that can be harmful, causing oxidative stress/cell damage - reactive oxygen species are unstable oxygen-containing molecules that can damage cells).

• Takes Polar drugs (water-soluble) or the products of Phase I, and attaches ("conjugates") a chemical group onto them: Glucuronidation, Acetylation, Sulfation, Methylation. These are all reactions where the body bolts on a small molecule (glucuronic acid, acetyl group, sulfate, or methyl group) to make the drug even MORE water-soluble.
• Result: "Very polar, hydrophilic metabolite (except acetylated metabolite)" - meaning the drug is now water-loving enough to be flushed out in urine easily. (Acetylation is the odd one out - it doesn't necessarily make things more water soluble.)
• Final step: Excretion via serum (blood, then filtered by kidney) → urine, sweat, or bile (which goes into stool).

Elimination of drugs

• "Capacity-limited elimination (ie, constant amount of drug eliminated per unit time). Cp ↓ linearly with time." This means the body's elimination machinery (usually an enzyme) is overwhelmed/saturated - it's working at max capacity already, so no matter how much drug is present, only a fixed AMOUNT (say, 10mg per hour) gets removed, not a fixed percentage. On a graph, the concentration falls in a straight line (linear), not a curve.
• "Examples of drugs - Phenytoin, Ethanol, and Aspirin (at high or toxic concentrations)." Mnemonic-worthy: PEA. These common drugs, when levels get high enough, saturate their metabolizing enzymes and become zero-order.
• "A PEA is round, shaped like the '0' in zero-order." Cute memory trick - a pea is round like the number "0."
• Graph: Zero-order shows a straight declining line; the elimination rate is constant (always removing the same amount, e.g., 2 units/hour) - this is shown as the "slope" of the line staying the same throughout. Note the half-life actually SHORTENS as concentration falls (since a fixed amount is removed regardless of concentration, that fixed amount becomes a bigger fraction of a smaller pool) - "Time of t1/2 ↓ as concentration ↓."

• "Rate of first-order elimination is directly proportional to the drug concentration (ie, constant fraction of drug eliminated per unit time). Cp ↓ exponentially with time. Applies to most drugs." This is the NORMAL way most drugs are eliminated - the body removes a constant PERCENTAGE (not a fixed amount) each time period. So if you have more drug, more gets removed in absolute terms, but the fraction/percentage removed stays the same. This produces an exponentially curving decline (fast drop when levels are high, slower drop as levels get low) - and this gives a CONSTANT half-life, which is why half-life is meaningful mostly for first-order drugs.
• Graph: Shows an exponential/curving decline; note "Time of t1/2 is constant regardless of concentration" - the half-life stays the same (e.g., always takes the same number of hours to halve, whether starting high or low).

PAGE 231 - URINE pH AND DRUG ELIMINATION

• "Ionized species are trapped in urine and cleared quickly. Neutral forms can be reabsorbed."
  • Drug molecules can exist in two forms depending on the surrounding pH: ionized (carries an electric charge, +/-) or neutral/non-ionized (no charge).
  • Charged (ionized) molecules cannot cross the fatty cell membranes lining the kidney tubules, so once they're ionized in urine, they stay stuck there ("trapped") and get flushed out.
  • Neutral (uncharged) molecules CAN slip back across the membrane and be reabsorbed into the blood, meaning they escape and stay in the body longer.

• "Examples: phenobarbital, methotrexate, aspirin (salicylates). Treat overdose with sodium bicarbonate to alkalinize urine."
  • These drugs are weak acids. Giving sodium bicarbonate (a base) makes the urine more alkaline (basic, high pH).
  • Chemistry shown: RCOOH ⇌ RCOO⁻ + H⁺ — RCOOH is the neutral (protonated, lipid-soluble) form of a weak acid drug; in alkaline (basic) urine, it gives up a proton (H⁺) and becomes RCOO⁻, the ionized/charged (trapped, water-soluble) form.
  • So: alkaline urine → traps weak acids as their charged form → they can't be reabsorbed → excreted faster. This is literally the antidote strategy for aspirin overdose.

• "Examples: tricyclic antidepressants (TCAs), amphetamines. Trapped in acidic environments. For severe alkalosis, treat with ammonium chloride to acidify urine."
  • Chemistry shown: RNH3⁺ ⇌ RNH2 + H⁺ — RNH3⁺ is the ionized/charged (trapped) form of a weak base drug, and RNH2 is the neutral, lipid-soluble form.
  • Weak bases get trapped (ionized, charged) when the urine is ACIDIC (low pH), because acidic conditions favor them keeping an extra H⁺ (staying protonated/charged).
  • Ammonium chloride is given to acidify the urine, useful in specific circumstances (like severe metabolic alkalosis).
• "TCA toxicity is initially treated with sodium bicarbonate to overcome the sodium channel-blocking activity of TCAs. This treats cardiac toxicity, but does not accelerate drug elimination."
  • This is an important clinical nuance: in a tricyclic antidepressant (TCA) overdose, doctors give sodium bicarbonate NOT to trap the drug in urine (that would actually require acidifying urine, which is dangerous and not done), but because bicarbonate directly counteracts the TCA's toxic effect on the heart's sodium channels (which causes dangerous heart rhythm problems). It's a totally separate mechanism from the "urine trapping" concept.

pKa

• "pH at which drugs (weak acid or base) are 50% ionized and 50% nonionized. The pKa represents the strength of the weak acid or base."
  • pKa is a fixed chemical property of each drug molecule - the specific pH value where exactly half the molecules are in the charged form and half in the neutral form.
  • Graph: X-axis = pH (0-14, ranging acidic to basic), Y-axis = % of drug that is ionized. The weak acid curve rises with increasing pH (more ionized as it gets more basic), while the weak base curve falls with increasing pH (less ionized as it gets more basic) - they cross at the pKa (here shown as 9.2 for illustration), where both are 50% ionized.
  • "↓pKa = more acidic" and "↑pKa = more basic" - just describing that a lower pKa number indicates a stronger acid tendency, higher pKa indicates more basic tendency.

PAGE 232 - EFFICACY vs POTENCY

Efficacy

• "Maximal effect a drug can produce (intrinsic activity). Represented by the y-value (Emax). ↑ y-value = ↑ efficacy."
  • Efficacy = how big of an effect the drug can produce at its absolute best/maximum dose - it's about the CEILING of effect, regardless of how much drug you need to get there.
• "Unrelated to potency (ie, efficacious drugs can have high or low potency)." A drug can need a huge dose (low potency) but still be able to achieve a very strong maximal effect (high efficacy) - the two properties are independent.
• "Partial agonists have less efficacy than full agonists." (Agonist = a drug that activates a receptor to produce a biological effect, like a key that turns a lock.) A full agonist can fully activate the receptor to its maximum possible effect. A partial agonist binds the same receptor but can never reach that ceiling, no matter how much you give - it has lower Emax.
• Graph "Relative Efficacy": X-axis = Log(drug dose), Y-axis = % Maximal effect. Drug A reaches a higher Emax (ceiling) than Drug B - the vertical gap between their plateaus is "Δ Efficacy" (difference in efficacy).

Potency

• "Amount of drug needed for a given effect. Represented by the x-value (EC50). ↓ EC50 = ↑ potency."
  • Potency = how little drug you need to get a certain effect. EC50 = the concentration/dose needed to achieve 50% of the maximum effect.
  • If a drug needs a tiny dose to work (low EC50), it's very potent. If it needs a huge dose, it's less potent.
• "Unrelated to efficacy (ie, potent drugs can have high or low efficacy)." Again, independent properties - a very small dose (potent) drug might still only produce a weak maximal effect (low efficacy).
• Graph "Relative Potency": Drug A reaches 50% effect at a lower dose than Drug B (its EC50 is further left/smaller), so Drug A is MORE potent. "EC = Effective concentration."

PAGE 233 - RECEPTOR BINDING & THERAPEUTIC INDEX

Receptor binding graphs (comparing agonist alone vs agonist + different antagonist types)

• Agonist: a drug that binds a receptor and activates it (turns the lock, opens the door - produces an effect).
• Antagonist: a drug that blocks a receptor without activating it (jams the lock so the key can't work).
• Competitive antagonist: binds the SAME site as the agonist, and competes with it - can be "out-competed" if you add enough agonist.
• Noncompetitive antagonist: binds a DIFFERENT site (allosteric site) and changes the receptor's shape so the agonist can't work properly, no matter how much agonist you add.
• Partial agonist: activates the receptor but only weakly (never reaches full effect even alone).
• Inverse agonist: binds the SAME receptor as an agonist but produces the OPPOSITE effect by shutting down the receptor's baseline ("constitutive") activity.

• Graphs described: Each shows "Agonist" alone as one curve (100% effect at top), then a second curve showing what happens when you add the antagonist type:
  • With competitive antagonist: curve shifts right (needs more agonist dose) but eventually still reaches 100% - "reduced potency" only.
  • With noncompetitive antagonist: curve's top gets capped below 100% - "reduced efficacy," can't be overcome by more agonist.
  • With partial agonist alone (compared to full agonist): reaches a lower plateau, and its own potency (EC50 position) is a separate/independent property.

Therapeutic index (TI)

• "Measurement of drug safety." How big is the gap between a dose that helps you and a dose that hurts/kills you?
• Formula: TI = TD50 / ED50 = median toxic dose / median effective dose.
  • ED50 = the dose at which 50% of a population/animals get the desired therapeutic effect.
  • TD50 = the dose at which 50% of a population/animals experience toxicity (harmful effects).
  • A BIG gap between these (high TI) = safer drug, because you'd need a much higher dose to cause harm than to get benefit.
• "Therapeutic window - range of drug concentrations that can safely and effectively treat disease." The "sweet spot" dose range - enough to work, not so much that it's dangerous.
• "Safer drugs have higher TI values. Drugs with lower TI values frequently require monitoring (eg, warfarin, theophylline, digoxin, antiepileptic drugs, lithium; Warning! These drugs are lethal!)." These are all "narrow therapeutic index" drugs - the dose that works is dangerously close to the dose that harms, so blood levels must be checked regularly.
• "LD50 (lethal median dose) often replaces TD50 in animal studies." In animal research, instead of measuring "toxic dose in 50%," they often literally measure the dose that kills 50% of test animals (LD50 - lethal dose 50%), used as a proxy for toxicity threshold when studying new drugs before human trials.
• Graph: X-axis = Log(drug concentration), Y-axis = % of patients responding. Shows three overlapping curves: "Efficacy" curve (rises first, showing therapeutic benefit), then "Toxicity" curve (rises later at higher doses), with the "Therapeutic Index" being the horizontal gap between the ED50 (effective dose 50) and TD50 (toxic dose 50) points.

PAGE 234 - DRUG EFFECT MODIFICATIONS & AUTONOMIC RECEPTORS

Drug effect modifications (how two drugs interact when combined)

Autonomic receptors (the diagram)

• Preganglionic neuron: the first nerve in the chain, starting at the spinal cord (sympathetic) or brainstem (parasympathetic), running to a relay station called a "ganglion."
• Postganglionic neuron: the second nerve, running from the ganglion to the actual target organ/tissue.
• ACh (acetylcholine): the chemical messenger (neurotransmitter) released by ALL preganglionic neurons (both sympathetic and parasympathetic) at the ganglion, acting on Nn receptors (nicotinic receptors, subtype found at ganglia).
• Parasympathetic: long preganglionic neuron, short postganglionic neuron; the postganglionic neuron also releases ACh, acting on target organs via M1, M2, M3 (muscarinic receptors) causing effects in smooth muscle, glands, heart.
• Sympathetic: short preganglionic neuron, long postganglionic neuron (running through the "sympathetic chain," a series of ganglia alongside the spinal cord); the postganglionic neuron releases NE (norepinephrine), acting on α1, α2, β1, β2 receptors on target organs like smooth muscle, cardiac muscle, blood vessels.
• Special exception - Sweat glands: even though sweating is triggered by the SYMPATHETIC system, the postganglionic neuron to sweat glands unusually releases ACh (not NE), acting on M3 receptors - this is called a "cholinergic sympathetic" fiber - the text calls this a "chold sweat" (play on words: "cold sweat"/cholinergic sweat) as a memory trick.
• Adrenal medulla: a special case - it's essentially a "modified ganglion." The preganglionic sympathetic neuron directly innervates it and it releases hormones Epinephrine (Epi) and Norepinephrine (NE) straight into the blood (not just locally, but as circulating hormones affecting the whole body) via ACh acting on Nn receptors.
• "Pelvic splanchnic nerves and CNs III, VII, IX, and X are part of the parasympathetic pathway." These are specific named nerves (cranial nerves 3, 7, 9, 10, plus pelvic splanchnic nerves) that carry parasympathetic fibers to various organs (eye, salivary glands, heart/lungs/gut, pelvic organs).
• Somatic (voluntary) pathway: shown separately - a single neuron runs directly from the spinal cord to skeletal muscle (no ganglion relay), releasing ACh onto Nm receptors at the neuromuscular junction (this controls voluntary movement, unlike the autonomic system).

PAGE 235 - ACETYLCHOLINE RECEPTORS & PAIN TRANSMISSION

Acetylcholine receptors

• "Nicotinic ACh receptors are ligand-gated channels allowing efflux of K+ and influx of Na+ (and in some cases Ca2+)."
  • A ligand-gated channel is a receptor that is also a physical pore/channel - when the chemical messenger (ligand, here ACh) binds it, the channel physically opens, letting ions flow through immediately. This is FAST signaling (electrical, milliseconds).
  • When ACh binds nicotinic receptors, sodium (Na+) rushes INTO the cell and potassium (K+) rushes OUT - this shifts the cell's electrical charge, triggering activity (like muscle contraction or nerve firing).
• "Two subtypes: Nn (found in autonomic ganglia, adrenal medulla) and Nm (found in neuromuscular junction of skeletal muscle)." Nn = nicotinic receptors at the "relay stations" of the autonomic system (and the adrenal gland); Nm = nicotinic receptors specifically where nerves meet skeletal muscle to cause movement.
• "Muscarinic ACh receptors are G-protein-coupled receptors that usually act through 2nd messengers (cholinergic glands (sympathetic))."
  • G-protein-coupled receptors (GPCRs) are a different, SLOWER type of receptor - instead of opening a channel directly, binding triggers a chain of internal chemical signals ("2nd messengers" - internal signaling molecules like cAMP) that eventually produce an effect. This is slower but can be amplified/more complex than direct channel opening.
  • "5 subtypes: M1-5, found in heart, smooth muscle, brain, exocrine glands, and on sweat glands (cholinergic sympathetic)." M1 through M5 are the five muscarinic receptor subtypes distributed across different organs; note again the special sweat gland exception mentioned on page 234.

Pain transmission

• "Pain signals transmitted to the CNS in response to mechanical, thermal, or chemical stimuli." The CNS = Central Nervous System (brain + spinal cord). Nociceptive pain = pain from an actual physical stimulus (like a cut, burn, or chemical irritant) - it's the body's normal warning system.
• "Transient receptor potential vanilloid ligand receptors activation. Signals transmitted by Aδ fibers (sharp, acute pain) or C fibers (dull, throbbing, chronic pain)."
  • TRPV (transient receptor potential vanilloid) receptors are specialized sensor proteins on nerve endings that detect heat, chemicals (like capsaicin from chili peppers), or tissue damage, and turn that into a pain signal.
  • Aδ fibers = a type of nerve fiber that is thin but somewhat insulated (myelinated), carrying signals FAST - responsible for the initial "sharp, quick" pain you feel immediately after an injury.
  • C fibers = thinner, uninsulated (unmyelinated) fibers that carry signals SLOWLY - responsible for the "dull, aching, throbbing" pain that lingers after the sharp pain fades.

1. Transduction - converting the physical/chemical stimulus into an electrical nerve signal at the site of injury. "Blocked by local anesthetics, α2-agonists, gabapentinoids, NSAIDs, acetaminophen, glucocorticoids" - these drugs work at the injury site to prevent the pain signal from ever starting (e.g., NSAIDs block inflammatory chemicals that would trigger pain receptors).
2. Transmission - the signal traveling up the nerve fiber and spinal cord toward the brain. "Blocked by local anesthetics, α2-agonists, opioids" - these interrupt the signal as it travels along nerves.
3. Modulation - the spinal cord/brain adjusting (amplifying or dampening) the pain signal before it's fully perceived. "Blocked by TCAs (tricyclic antidepressants), SNRIs (serotonin-norepinephrine reuptake inhibitors), gabapentinoids" - these drugs affect the neurotransmitter systems in the spinal cord that modulate pain signals.
4. Perception - the final conscious experience of pain in the brain. "Blocked by α2-agonists, opioids, TCAs, SSRIs, SNRIs" - these act centrally in the brain to change how pain is consciously experienced.

• "Caused by neuronal dysfunction of the CNS or PNS." PNS = Peripheral Nervous System (all the nerves outside the brain/spinal cord). This pain arises from the NERVES themselves being damaged or malfunctioning, not from an external injury being actively sensed.
• "Transmitted via upregulation and persistent activation of voltage-gated Na+ channels." Damaged nerves become abnormally "trigger-happy" - their sodium channels (which normally open briefly during a nerve signal) become overactive and increase in number, causing spontaneous, ongoing pain signals even without a real stimulus.
• "Example: diabetic peripheral neuropathy." Classic example - long-term high blood sugar in diabetes damages peripheral nerves (especially in the feet/legs), causing burning, tingling, or shooting pain even without any actual injury happening.